Effect of ICD implantation on cardiovascular outcomes in patients with cardiac amyloidosis: A systematic review and meta-anaylsis.
appropriate ICD treatment
cardiac amyloidosis
heart failure
implantable cardioverter-defibrillator (ICD)
inappropriate ICD treatment
mortality
pulseless electrical activity
sudden cardiac death
systematic review and meta-analysis
ventricular tachycardia
Journal
Journal of cardiovascular electrophysiology
ISSN: 1540-8167
Titre abrégé: J Cardiovasc Electrophysiol
Pays: United States
ID NLM: 9010756
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
25
11
2019
revised:
26
03
2020
accepted:
24
04
2020
pubmed:
12
5
2020
medline:
30
6
2021
entrez:
12
5
2020
Statut:
ppublish
Résumé
Cardiac amyloidosis is associated with a high rate of sudden cardiac death (SCD). Whether implantable cardioverter-defibrillator (ICD) use in such patients prevents SCD is uncertain. This study assesses outcomes of ICD use in patients with cardiac amyloidosis. A systematic review and meta-analysis of data were performed after searching multiple databases and scientific sites pertaining to ICD use and cardiac amyloidosis. Of 8260 citations identified, six studies comprising 194 patients met inclusion criteria. Mean values and frequencies of patient characteristics were as follows: mean NT-proBNP: 6867.9 pg/mL, mean left ventricular ejection fraction: 48.1%, heart failure: 67%, nonsustained ventricular tachycardia: 51%, syncope: 21%, and secondary prevention: 33%. During the mean follow-up period of 18.21 months, 18% of patients received appropriate ICD treatment and 5% received inappropriate ICD treatment. The mortality rate was 31%. Two studies assessed the difference between patients with appropriate ICD treatment and patients with absence of appropriate ICD treatment. There was no difference between the two groups when stratified on multiple selected third variables except for two subgroups. Male gender was associated with a higher rate of appropriate ICD treatment, whereas New York Heart Association class III or IV heart failure patients was associated with a lower rate of appropriate ICD treatment. The frequency of appropriate ICD treatment in cardiac amyloidosis is low and is not predicted by nonsustained ventricular tachycardia. Male gender is associated with appropriate ICD treatment. New York Heart Association class III or IV heart failure is associated with lower rate of appropriate ICD treatment.
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1749-1758Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Falk RH, Alexander KM, Liao R, Dorbala S. AL (light-chain) cardiac amyloidosis. A review of diagnosis and therapy. J Am Coll Cardiol. 2016;68(12):1323-1341. https://doi.org/10.1016/j.jacc.2016.06.053
Chamarthi B, Dubrey SW, Cha K, Skinner M, Falk RH. Features and prognosis of exertional syncope in light-chain associated AL cardiac amyloidosis. Am J Cardiol. 1997;80(9):1242-1245.
Kristen AV, Dengler TJ, Hegenbart U, et al. Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death. Heart Rhythm. 2008;5(2):235-240. https://doi.org/10.1016/j.hrthm.2007.10.016.
Donnelly JP, Hanna M. Cardiac amyloidosis: an update on diagnosis and treatment. Cleve Clin J Med. 2017;84(12 Suppl 3):S12-S26. https://doi.org/10.3949/ccjm.84.s3.02
Wechalekar AD, Schonland SO, Kastritis E, et al. A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood. 2013;121(17):3420-3427. https://doi.org/10.1182/blood-2012-12-473066.
Obici L, Perfetti V, Palladini G, Moratti R, Merlini G. Clinical aspects of systemic amyloid diseases. Biochim Biophys Acta. 2005;1753(1):11-22. https://doi.org/10.1016/j.bbapap.2005.08.014
Banypersad SM, Moon JC, Whelan C, Hawkins PN, Wechalekar AD. Updates in cardiac amyloidosis: a review. J Am Heart Assoc. 2012;1(2):e000364. https://doi.org/10.1161/JAHA.111.000364
Falk RH, Rubinow A, Cohen AS. Cardiac arrhythmias in systemic amyloidosis: correlation with echocardiographic abnormalities. J Am Coll Cardiol. 1984;3(1):107-113. https://doi.org/10.1016/S0735-1097(84)80436-2
Dubrey SW, Bilazarian S, LaValley M, Reisinger J, Skinner M, Falk RH. Signal averaged electrocardiography in patients with AL (primary) amyloidosis. Am Heart J. 1997;134(6):994-1001.
Hamon D, Algalarrondo V, Gandjbakhch E, et al. Outcome and incidence of appropriate implantable cardioverter-defibrillator therapy in patients with cardiac amyloidosis. Int J Cardiol. 2016;222:562-568. https://doi.org/10.1016/j.ijcard.2016.07.254.
Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: executive summary. Circulation. 2018;138(13):e210-e271. https://doi.org/10.1161/CIR.0000000000000548.
Varr BC, Zarafshar S, Coakley T, et al. Implantable cardioverter-defibrillator placement in patients with cardiac amyloidosis. Heart Rhythm. 2014;11(1):158-162. https://doi.org/10.1016/j.hrthm.2013.10.026
Rezk T, Whelan CJ, Lachmann HJ, et al. Role of implantable intracardiac defibrillators in patients with cardiac immunoglobulin light chain amyloidosis. Br J Haematol. 2017;182:145-148. https://doi.org/10.1111/bjh.14747.
Lin G, Dispenzieri A, Kyle R, Grogan M, Brady PA. Implantable cardioverter defibrillators in patients with cardiac amyloidosis. J Cardiovasc Electrophysiol. 2013;24(7):793-798. https://doi.org/10.1111/jce.12123
Chuzi S, Rosenblatt A, Knight BP, Anderson AS. Abstract 18064: outcome of implantable defibrillator therapy in patients with cardiac amyloidosis. Circulation. 2018;136(A18064):1-5.
Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. London, UK: The Cochrane Collaboration; 2011. www.handbook.cochran.org
Sidwell K. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. Ottawa Hosp Res Inst. 2013;3:1-4. https://doi.org/10.2307/632432.
Viechtbauer W. Conducting meta-analyses in R with the metafor Package. J Stat Softw. 2010;36(3):1-48. https://www.jstatsoft.org/v036/i03
Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346(12):877-883. https://doi.org/10.1056/NEJMoa013474.
Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352(3):225-237. https://doi.org/10.1056/NEJMoa043399.
Sticherling C, Arendacka B, Svendsen JH, et al. Sex differences in outcomes of primary prevention implantable cardioverter-defibrillator therapy: combined registry data from eleven European countries. Europace. 2018;20(6):934-970. https://doi.org/10.1093/europace/eux176.
Dhoble A, Khasnis A, Olomu A, Thakur R. Cardiac amyloidosis treated with an implantable cardioverter defibrillator and subcutaneous array lead system: report of a case and literature review. Clin Cardiol. 2009;32(8):63-65. https://doi.org/10.1002/clc.20389
Hashimura H, Ishibashi-Ueda H, Yonemoto Y, et al. Late gadolinium enhancement in cardiac amyloidosis: attributable both to interstitial amyloid deposition and subendocardial fibrosis caused by ischemia. Heart Vessels. 2016;31(6):990-995. https://doi.org/10.1007/s00380-015-0658-0.
Dorbala S, Vangala D, Bruyere J, et al. Coronary microvascular dysfunction is related to abnormalities in myocardial structure and function in cardiac amyloidosis. JACC Heart Fail. 2014;2(4):358-367. https://doi.org/10.1016/j.jchf.2014.03.009.
Palladini G1, Malamani G, Cò F, et al. Holter monitoring in AL amyloidosis: prognostic implications. PACE - Pacing Clin Electrophysiol. 2001;24:1228-1233.
Sayed RH, Rogers D, Khan F, et al. A study of implanted cardiac rhythm recorders in advanced cardiac AL amyloidosis. Eur Heart J. 2015;36(18):1098-1105. https://doi.org/10.1093/eurheartj/ehu506.
Køber L, Thune JJ, Nielsen JC, et al. Defibrillator implantation in patients with nonischemic systolic heart failure. N Engl J Med. 2016;375(13):1221-1230. https://doi.org/10.1056/NEJMoa1608029.